Develops investigational medicines for people with recurrent genital herpes, hepatitis B and hepatitis delta, as well as transplant-related herpesvirus infections.
10-K for FY2025, filed Mar 19, 2026We are a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives…View ↗
Partners pay for licensed rights and research work: fees may be paid when a license transfers or as research is performed, while development milestone payments and royalties depend on milestones or partner sales.
10-K for FY2025, filed Mar 19, 2026LicensesView ↗
The promises under the Company’s agreements may include research and development services to be performed by the Company on behalf of the…View ↗
Depending on facts and circumstances, the Company may record revenues from certain milestones in a reporting period before the milestone is…View ↗
The Company’s customers may be required to pay the Company sales-based milestone payments or royalties on future sales of commercial…View ↗
$72.3M
10-K for FY2025, filed Mar 19, 2026
$72.3M ↗
Gilead licensed the herpes program and is a development and commercialization partner.
10-K for FY2025, filed Mar 19, 2026
No. It lost $6.1M in FY2025.
Growing. Revenue grew 11.6x in 4 years, from $6.3M in FY2021 to $72.3M in FY2025, about 84% a year.
Herpes program licensed to Gilead
The older report said it was advancing a genital-herpes candidate toward clinical trials; the latest says Gilead licensed the herpes program and will take control of its development after the ongoing studies are complete.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 19, 2026Novel Antivirals Targeting Herpesviruses – Advancing (1) ABI-5366 (5366), a long-acting HSV-2 helicase inhibitor targeting high-recurrence…View ↗
Wider antiviral pipeline
The older report centered its strategy on hepatitis B core inhibitors alongside herpes and other antiviral programs. The latest describes programs for herpes, hepatitis delta, hepatitis B and transplant-related herpesviruses.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 19, 2026We are a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives…View ↗
HDV – Completing Phase 2 preparation activities and studies of ABI-6250 (6250), with Phase 2 initiation expected in the fourth quarter of…View ↗
HBV – Evaluating partnering opportunities for ABI-4334 (4334), for which we have initiated a structured process to find potential partners…View ↗
Transplant-Associated Herpesviruses – Advancing ABI-7272 (7272), our oral broad-spectrum NNPI for the treatment of transplant-associated…View ↗
Competes with GlaxoSmithKline, Enanta Pharmaceuticals, Arbutus Biopharma, Vir Bio, Mirum Pharmaceuticals, Huahui Health, Aligos Therapeutics, Innovative Molecules, and AiCuris Anti-infective Cures
10-K for FY2025, filed Mar 19, 2026The pharmaceutical and biotechnology industry is very competitive, and the development and commercialization of new drugs is influenced by…View ↗
Loading...